INZY Inozyme Pharma Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: INZY

Price (delayed)

$4.74

Market cap

$292.8M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.37

Enterprise value

$304.49M

Inozyme Pharma is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization. Through the company's in-depth understanding of the biological pathways involved in ...

Highlights
INZY's EPS is up by 23% year-on-year and by 6% since the previous quarter
The quick ratio has grown by 48% YoY but it has contracted by 18% from the previous quarter
The equity is up by 19% year-on-year but it has declined by 12% since the previous quarter
The company's debt rose by 37% QoQ
The company's net income fell by 6% YoY and by 4.4% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.inozyme.com
Peers: OMER OMGA

Key stats

What are the main financial stats of INZY
Market
Shares outstanding
61.77M
Market cap
$292.8M
Enterprise value
$304.49M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.08
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$67.84M
EBITDA
-$66.51M
Free cash flow
-$70.97M
Per share
EPS
-$1.37
Free cash flow per share
-$1.37
Book value per share
$2.27
Revenue per share
$0
TBVPS
$3.87
Balance sheet
Total assets
$200.85M
Total liabilities
$60.37M
Debt
$46.59M
Equity
$140.48M
Working capital
$181.56M
Liquidity
Debt to equity
0.33
Current ratio
13.36
Quick ratio
12.86
Net debt/EBITDA
-0.18
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-40.7%
Return on equity
-55.9%
Return on invested capital
-44%
Return on capital employed
-36.4%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

INZY stock price

How has the Inozyme Pharma stock price performed over time
Intraday
1.94%
1 week
6.76%
1 month
-33.89%
1 year
-18.56%
YTD
11.27%
QTD
-38.12%

Financial performance

How have Inozyme Pharma's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$75.65M
Net income
-$71.17M
Gross margin
N/A
Net margin
N/A
INZY's operating income is down by 10% year-on-year and by 4.5% since the previous quarter
The company's net income fell by 6% YoY and by 4.4% QoQ

Growth

What is Inozyme Pharma's growth rate over time

Valuation

What is Inozyme Pharma stock price valuation
P/E
N/A
P/B
2.08
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
INZY's EPS is up by 23% year-on-year and by 6% since the previous quarter
The equity is up by 19% year-on-year but it has declined by 12% since the previous quarter

Efficiency

How efficient is Inozyme Pharma business performance
The company's return on invested capital rose by 41% YoY and by 16% QoQ
The company's return on assets rose by 14% YoY and by 4.9% QoQ
INZY's ROE is down by 3.5% year-on-year

Dividends

What is INZY's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for INZY.

Financial health

How did Inozyme Pharma financials performed over time
The total liabilities has soared by 190% YoY and by 33% QoQ
Inozyme Pharma's current ratio has increased by 50% YoY but it has decreased by 18% from the previous quarter
The company's debt is 67% lower than its equity
The debt to equity has soared by 57% from the previous quarter
The company's debt rose by 37% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.